BioSyent Inc. (CVE:RX – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as C$16.58 and last traded at C$16.79, with a volume of 17273 shares trading hands. The stock had previously closed at C$16.00.
BioSyent Stock Down 5.4%
The company has a market cap of C$187.05 million, a P/E ratio of 19.37 and a beta of 1.11. The company has a debt-to-equity ratio of 6.85, a quick ratio of 6.91 and a current ratio of 2.07. The business’s fifty day moving average is C$15.35 and its two-hundred day moving average is C$14.84.
Insider Activity
In related news, Director Seyed Ahmad Ashrafi sold 1,884 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of C$14.65, for a total value of C$27,600.60. Following the transaction, the director owned 37,261 shares of the company’s stock, valued at C$545,873.65. This represents a 4.81% decrease in their ownership of the stock. Insiders sold a total of 5,635 shares of company stock valued at $85,368 in the last ninety days. 33.65% of the stock is currently owned by insiders.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Featured Articles
- Five stocks we like better than BioSyent
- DraftKings Falls 7.6%: Is Kalshi’s NFL Lead Really That Big?
- Gaming Your Portfolio: Should You Add Take-Two Ahead of GTA 6’s November Launch?
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
